EGFR and non-small cell lung carcinoma: <h4>Background and purpose</h4>Resistance to epithelial growth factor receptor gene (EGFR)-tyrosine kinase inhibitors, both intrinsic and acquired, presents a major challenge in EGFR mutant non-small cell lung carcinoma (NSCLC), with the T790M mutation being the most common acquired resistance mechanism.